Latest Breaking News On - Eyepoint pharmaceuticals nasdaq - Page 4 : comparemela.com

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

WATERTOWN, Mass., Dec. 04, 2023 EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal.

EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments

– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related .

EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023

EyePoint Pharmaceuticals Announces Presentations at Eyecelerator 2023, American Academy of Ophthalmology Annual Meeting 2023 and Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference 2023 -October 30, 2023 at 07:01 am EDT

WATERTOWN, Mass., Oct. 30, 2023 EyePoint Pharmaceuticals, Inc. , a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with retinal.